GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (BSP:G1LP34) » Definitions » Cyclically Adjusted PS Ratio

Galapagos NV (BSP:G1LP34) Cyclically Adjusted PS Ratio : 4.91 (As of May. 21, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Galapagos NV Cyclically Adjusted PS Ratio?

As of today (2024-05-21), Galapagos NV's current share price is R$7.46. Galapagos NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was R$1.52. Galapagos NV's Cyclically Adjusted PS Ratio for today is 4.91.

The historical rank and industry rank for Galapagos NV's Cyclically Adjusted PS Ratio or its related term are showing as below:

BSP:G1LP34' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.76   Med: 8.43   Max: 35.11
Current: 4.91

During the past years, Galapagos NV's highest Cyclically Adjusted PS Ratio was 35.11. The lowest was 4.76. And the median was 8.43.

BSP:G1LP34's Cyclically Adjusted PS Ratio is ranked better than
53.65% of 507 companies
in the Biotechnology industry
Industry Median: 5.55 vs BSP:G1LP34: 4.91

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Galapagos NV's adjusted revenue per share data for the three months ended in Mar. 2024 was R$5.132. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is R$1.52 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Galapagos NV Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Galapagos NV's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Cyclically Adjusted PS Ratio Chart

Galapagos NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 15.06 9.12 7.27 6.66

Galapagos NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.28 6.33 5.43 6.66 5.28

Competitive Comparison of Galapagos NV's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Galapagos NV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Cyclically Adjusted PS Ratio falls into.



Galapagos NV Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Galapagos NV's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=7.46/1.52
=4.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galapagos NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Galapagos NV's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=5.132/130.5518*130.5518
=5.132

Current CPI (Mar. 2024) = 130.5518.

Galapagos NV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 99.482 0.000
201409 1.337 99.195 1.760
201412 2.215 99.086 2.918
201503 1.659 99.423 2.178
201506 1.204 100.107 1.570
201509 0.641 100.245 0.835
201512 0.778 100.572 1.010
201603 0.916 101.653 1.176
201606 2.297 102.267 2.932
201609 0.859 102.118 1.098
201612 6.088 102.614 7.746
201703 2.458 103.972 3.086
201706 1.987 103.902 2.497
201709 2.006 104.170 2.514
201712 3.014 104.804 3.754
201803 3.001 105.419 3.716
201806 4.221 106.063 5.196
201809 8.581 106.618 10.507
201812 7.840 107.252 9.543
201903 2.623 107.876 3.174
201906 4.658 107.896 5.636
201909 48.010 107.470 58.321
201912 7.428 108.065 8.974
202003 7.515 108.550 9.038
202006 8.952 108.540 10.767
202009 12.378 108.441 14.902
202012 14.950 108.511 17.987
202103 11.427 109.522 13.621
202106 12.924 110.305 15.296
202109 6.084 111.543 7.121
202112 -8.154 114.705 -9.281
202203 11.229 118.620 12.359
202206 11.171 120.948 12.058
202209 10.741 124.120 11.298
202212 -15.489 126.578 -15.975
202303 4.926 126.528 5.083
202306 21.743 125.973 22.533
202309 9.527 127.083 9.787
202312 -17.068 128.292 -17.369
202403 5.132 130.552 5.132

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Galapagos NV  (BSP:G1LP34) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Galapagos NV Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV (BSP:G1LP34) Business Description

Industry
Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Galapagos NV (BSP:G1LP34) Headlines

No Headlines